BTX-1801 kills certain bacteria in vitro and may well work in people to prevent common surgical site infections. BOT is doing a small Phase 2 clinical trial now at a hospital in Perth, so we will know quite soon. The clinical trials will eventually tell us if and when syzygy is achieved, and just because some members of a family of molecules also have mind altering properties doesn't prove anything either way.
